Robert Ferris, MD, PhD (IMAGE)
Caption
“In our clinical trial, we compared two different combinations of immunotherapy drugs to using a single immunotherapy drug, and found that either combination regimen doubled or tripled the response rate versus the single immunotherapy, and led to a survival benefit. Up to a third of patients who received two drugs saw over 50 percent of their tumor disappear after only one month of treatment," said Robert L. Ferris, MD, PhD, executive director of UNC Lineberger Comprehensive Cancer Center.
Credit
UPMC
Usage Restrictions
None
License
Original content